CHANCE - Candesartan in Hypertrophic Cardiomyopathy

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00430833
• Date of registration: 31/01/2007
• Prospective Registration: Yes
• Primary sponsor: Charles University, Czech Republic
• Public title: CHANCE - Candesartan in Hypertrophic Cardiomyopathy
• Scientific title: Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study
• Date of first enrolment: March 2007
• Recruitment status: Active, not recruiting
• URL: http://clinicaltrials.gov/show/NCT00430833
• Study type: Interventional
• Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind
• Phase: Phase 2

Countries of recruitment

Czech Republic

Contacts

• Name: Martin Penicka, PhD
• Affiliation: Charles University, Prague, Czech Republic

Key inclusion & exclusion criteria

Inclusion Criteria:

- HCM defined on the basis of echocardiographic criteria showing a nondilated,
hypertrophied left ventricle (any wall thickness > 15 mm) in the absence of known
causes of LV hypertrophy hypertension or valvular disease

Exclusion Criteria:

- Hypertrophic obstructive cardiomyopathy defined as presence of resting gradient in
left ventricular outflow tract ³30 mmHg or in righ ventricular outflow tract ³15 mmHg
at Doppler echocardiography;

- Atrial fibrillation;

- Treatment with ACE inhibitors or AT1-R antagonists any time in the past;

- Contraindications to AT1-R antagonists;

- Coronary artery disease, renal failure, hepatic disorders or serious intercurrent
illness limiting survival; and

- Poor echocardiographic image quality.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Hypertrophic Cardiomyopathy

Intervention(s)

Drug: candesartan

Secondary ID(s)

9164

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

AstraZeneca